Danzhijiangtang capsule protects vasculopathy of T2DM: an evaluation based on the expression of Wnt/β-catenin

Abstract

Abstract:

AIM: To evaluate the protective effect of Danzhijiangtang capsule on vasculopathy of type 2 diabetes mellitus (T2DM) patients by observing the expression of Wnt/β-catenin, GSK-3β, and the change of carotid intima media thickness (IMT) and plaque area. METHODS: One hundred and two T2DM patients were randomly allocated into the control group and the treatment group (n=51). Both groups received conventional therapy (hypoglycemic drugs orally), while the treatment group was given extra Danzhijiangtang capsule. Therapy was conducted for 16 weeks.RESULTS:The total effective rate of the treatment group was significantly better than that of the control group (84.31% vs. 64.71%, P<0.05). Traditional Chinese Medicine (TCM) symptom scores, FPG, 2 hPG, HbA1c, TC, TG, LDL, HDL, carotid intima media thickness and plaque area were improved in both groups. Compared with the control group, TCM scores, 2 hPG, HbA1, TG and LDL decreased significantly (P<0.05 or P<0.01) in the treatment group, which also presented better improvement of IMT (P<0.05) though the comparison of plague area exhibited no significant difference (P＞0.05); The expressions of Wnt/β-catenin and GSK-3β also decreased significantly in the treatment group (P<0.05). CONCLUSION: Danzhijiangtang capsule can alleviate the clinical symptoms of T2DM, and can improve or even reverse carotid atherosclerosis to a certain extent.

Key words: type 2 diabetes mellitus, vasculopathy, Danzhijiangtang capsule, Wnt/&beta, chain protein, glycogen synthase kinase-3

CLC Number:

R969.1

NI Yingqun, XIE Fengtao, FANG Zhaohui. Danzhijiangtang capsule protects vasculopathy of T2DM: an evaluation based on the expression of Wnt/β-catenin[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(5): 531-537.

References

［1］张国钦，陈盛玉，张玉华，等.天津市城区肺结核合并糖尿病的流行病学特征分析［J］．中国慢性病防治与控制，2016，24(1):14-18.
［2］Yang W, Lu J, Weng J, et al．Prevalence of diabetes among men and women in China ［J］．N Engl J Med，2010,362(12):1091-1101.
［3］雷尚芳，鲍升娟，郭俐宏，等.红景天胶囊对兔急性心肌缺血再灌注损伤的保护作用［J］. 长春中医药大学学报，2015，31（4）：673-676.
［4］沈安鲁，王靓，彭代银，等.丹蛭降糖胶囊干预2型糖尿病血管并发症的实验研究［J］. 广西中医药大学学报，2015，18（4）：1-4.
［5］中华医学会糖尿病学分会．中国2型糖尿病防治指南2013年版［M］．北京：北京大学医学出版社，2013：5．
［6］张耿，邓炳取，占达良.血清25－羟维生素D3水平与 2 型糖尿病患者大血管病变的相关性研究［J］.川北医学院学报，2015，6(30):831-833.
［7］赵春滔，张志强，王志军. 颈动脉内中膜厚度、颈动脉斑块总积分及P 选择素水平与急性冠状动脉综合征患者冠状动脉病变的关系［J］.中国心血管杂志，2015，20（6）：447-451.
［8］中华医学会糖尿病学分会．糖尿病中医防治指南［M］．北京：中国中医药出版社，2007：45．
［9］吴勉华，王新月．中医内科学［M］．北京：中国中医药出版社，2012：342-347．
［10］中华人民共和国卫生部．中药新药临床研究指导原则［S］．北京：中国医药科技出版社，2002，233-236．
［11］Fang ZH, Liu Y, Bao TT, et al. Effect of Danzhijiangtang capsule on monocyte chemoattractant protein-1 mRNA expression innewly diagnosed diabetes subclinical vascular lesions［J］. World J Gastroenterol, 2013,19(19):2963-2968.
［12］方朝晖,赵进东,王金萍,等.丹蛭降糖胶囊联合阿托伐他汀钙对糖尿病不伴有高血压病患者颈动脉内膜中层厚度的影响［J］.世界科学技术:中医药现代化, 2013,15(5):884-890.
［13］陆瑞敏,方朝晖.益气养阴活血法对新诊断2型糖尿病患者血管内皮钙黏蛋白水平的影响［J］ .中医药临床杂志,2012,24(2):111-113.
［14］倪英群，方朝晖，王飞. 丹蛭降糖胶囊保护2型糖尿病血管内皮功能的多普勒超声评价［J］. 中国临床药理学与治疗学，2006，11（12）：1427-1429.
［15］张亚楠，刑瑜，李辉，等. 颈动脉粥样硬化与脑梗死的临床研究相关分析［J］.脑与神经疾病杂志，2016，24（2）：108-112.
［16］方朝晖，赵进东，刘怀珍，等.丹蛭降糖胶囊对T2DM气阴两虚夹瘀证患者降糖作用有效性的系统评价［J］. 浙江中医药大学学报，2014，38（12）：1400-1403.
［17］高家荣，方朝晖，庄星星，等.基于UPLC/QTOF-MS技术的丹蛭降糖胶囊防治2型糖尿病血管病变大鼠的血清代谢组学研究［J］.中国医院药学杂志，2016，36（11）：878-883.
［18］吴元洁，方朝晖，郑书国，等.丹蛭降糖胶囊联合运动对糖尿病大鼠胰腺氧化应激及胰岛功能的影响［J］. 中国中西医结合杂志，2012，32（11）：1531-1534.
［19］倪英群，方朝晖.不同强度运动联合中药对葡萄糖耐量减退大鼠血管内皮功能的影响［J］. 中国中医药信息杂志，2016，23（4）：54-57.
［20］江婷，方朝晖，郭呈林，等.丹蛭降糖胶囊联合生活方式干预2型糖尿病患者颈动脉斑块的临床观察［J］. 成都中医药大学学报，2014，37（1）:56-59.
［21］倪英群,方朝晖, 王欢.益气活血中药对糖耐量减低人群血管内皮ET-1、vWF水平的影响［J］. 中国中医急症，2012，21（5）：689-690.
［22］郭澄,苏中武,李承祜,等.中药菟丝子保肝活性的研究［J］.时珍国药研究,1992,3(2):62-64.
［23］Miura T，Tanno M．Mitochondria and GSK- 3beta in cardioprotection against ischemia/reperfusion injury［J］．Cardiovasc Drugs Ther，2010，24(3):255-263．
［24］刘铭心，陈菊屏.Wnt信号通路与肺纤维化的研究进展［J］.现代医药卫生，2016，32（1）：83-85.
［25］Lee HC，Kim M，Wands JR.Wnt/frizzled signaling in hepatocellularcarcinoma［J］.Front Biosci，2006，11: 1901-1915.
［26］Moon RT，Bowerman B，Boutros M，et al.The promise and perils of Wnt signaling through beta-catenin［J］.Science，2002，296(5573):1644-1666.
［27］张炳英，王红，任莉，等.颈动脉粥样硬化与缺血性脑血管病的关系［J］.中国医学影像技术，2004，20(2):243-245.

[1]	MA Yan, TIAN Gaopeng, SHI Xingwen, SUN Ting, XIE Jingjing, ZHEN Donghu. Correlation between 25(OH)D and metabolically related fatty liver in T2DM population [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 1018-1026.
[2]	HOU Ruiying, GUO Lige, JIAO Weijie, DU Lei, WU Guiyue, ZHAO Xu. Effects of Xiaokeshu recipe on levels of serum inflammatory factors in type2 diabetic rats and its mechanism [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 377-382.
[3]	ZHAI Weiwei, YU Qiaoling, LIU Ping, QIU Bo, WU Huizhen. Research progress of finerenone in the treatment of type 2 diabetes mellitus complicated with chronic kidney disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(9): 1067-1074.
[4]	LU Senlin, LIU Xinyuan, WANG Jili, HUANG Xiaofei. Research progress of virus-mediated gene therapy in type 2 diabetes mellitu [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(7): 800-807.
[5]	DAI Hongyu, YANG Kun, HU Ruchun, ZHOU Hongmei, MA Peimin, HAO Qian. Duration time and effectiveness of 0.25%ropivacaine for sciatic nerve block in patients with diabetes [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(11): 1278-1284.
[6]	XU Yongxia, XIE Mingzhu, GONG Muxue, HUANG Jiaying, ZHAO Li, ZHU Defa. Effects of 25(OH)D on islet β-cells function in the elderly with type 2 diabetes [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(9): 1021-1026.
[7]	ZHAO Hailing, ZHANG Haojun, ZHAO Tingting, YAN Meihua, DONG Xi, MA Liang, LI Ping. Association between the polymorphism of PNPLA2 gene and the risk of ischemic stroke in type 2 diabetic patients in Chinese Han Population [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(6): 664-669.
[8]	YE Shengkai, WEN Jie, LIU Weiping, REN Xia, CHEN Haiying, DU Ying, LI Xue, ZHANG Ru, YU Li, ZHANG Biying. Effects of dapagliflozin on intima-medial thickness of carotid artery in type 2 diabetic mellitus patients [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(7): 814-819.
[9]	ZHANG Chunyan, FAN Xiaodong, QIN Yuan, KONG Wenqiang, ZHOU Chunyang, DU Biao. Markov model to assess long-term effects of teneligliptin in treatment of type 2 diabetes mellitus [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(1): 65-72.
[10]	YU Qinyun, SU Xiaogong, BAO Qiying, CHEN Xiaoyan. Effect of resveratrol on the Wnt/β-Catenin pathway in ovariectomized osteoporosis rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(6): 645-649.
[11]	SONG Meiqing. Effect of metformin on bone mineral density, insulin resistance and cytokines in type 2 diabetes mellitus patients with primary hypertension [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(6): 694-698.
[12]	LIU Chang, JIANG Daoli, LIU Xiaofang, XU Jia, WANG Lijue, WANG Qian, XU Ling, FANG Yi. Establishment of rat model of type 2 diabetes induced by streptozotocin combined with cerebral ischemic reperfusion injury [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(5): 518-525.
[13]	CHEN Hua, GONG Yi, ZHOU Baoshang, ZHANG Jing. MiR-200a alleviates renal interstitial fibrosis by inhibiting Wnt/β-catenin signaling pathway [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(4): 381-386.
[14]	WANG Chanyue, WANG Ye, ZHANG Peipei, CHEN Mingyue, YANG Hao, ZHU Manli, LI Linlin. Relationship of Fusobacterium nucleatum levels in gut microbiota with type 2 diabetes mellitus in Uygurs of Xinjiang [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(12): 1321-1325.
[15]	KONG Xiang, HUA Qiang, MENG Xiangjian, YAO Xinming, WANG Yong, XIA Libin. Clinical implications of circulating miRNA-101 expression level in patients with newly diagnosed type 2 diabetes mellitus [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(12): 1406-1409.